

Dr. Felix Paulussen




THE PROBLEM:

Colorectal cancer (CRC) is a common and deadly disease.


- 3rd most common cancer
- 2nd most deadly cancer
- Therapeutic void

No molecular targeted therapy!

patients deaths



Oncogenic activation
e.g. in colorectal cancer (CRC)



THE SOLUTION:

We developed two series of **peptide derived compounds** that address a key driver of **Wnt-dependent CRC (80%)**, the oncogene **β-catenin**.


These inhibit the **β-catenin/transcription factor interaction** and have shown **cellular activity**.

Crystal structures show that they bind to two different protein sites.

Thus, they provide an **ideal starting point** for the development of a **molecular targeted therapy!**

OUR PATH FORWARD:

We want to show **in vivo** proof-of-principle and are looking for funding and collaboration partners.



Prof. Tom Grossmann



VU Amsterdam
grossmannlab.com

